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DObjective: The introduction of aortic stent grafting in the treatment of thoracic aortic disease has pioneered
unique treatment options and gained rapid clinical adoption despite a paucity of long-term outcome data.
The purpose of this analysis is to examine all operations performed using thoracic aortic stent grafts at the Uni-
versity of Pennsylvania Health System.
Methods: A total of 502 operations involving thoracic aortic stent grafting were performed between April 1999
and April 2009. Patients were followed in a prospectively collected clinical perioperative registry, and long-term
outcomes were determined from administrative data sources. Aortic pathologies included aortic aneurysm, acute
aortic dissection (types A and B), hybrid arch repairs, reinterventions with additional stents, pseudoaneurysm,
chronic type B dissection, traumatic transection, penetrating aortic ulcer, and other unique indications.
Results: Patients’ mean age at the time of thoracic endovascular aortic repair was 70.1 12.4 years, and 51% of
the patients were aged more than 70 years. Some 41% of patients were female, and the majority of patients
(87%) were hypertensive. Overall 30-day mortality was 10.1%. Multivariable risk factors for 30-day mortality
included urgent/emergency, Stanford type A aortic dissection, perioperative spinal ischemia, type C aortic cov-
erage, hybrid arch operation, aortic transection, chronic renal failure, and age. Neurologic complications in-
cluded permanent complete or incomplete paraplegia in 17 patients (3.4%), reversible spinal cord ischemia
in 26 patients (5.1%), transient stroke in 16 patients (3.2%), and permanent stroke in 23 patients (4.6%).
Greater extent of aortic coverage was not associated with risk of spinal cord ischemia. Access complications,
stroke, and endoleaks diminished with increased operative experience over time. Risk factors for late mortality
included urgent/emergency indications, hybrid procedures, traumatic aortic transection, age, perioperative pa-
ralysis, and chronic renal failure. Patients undergoing stent grafting for type B dissection were more likely to
survive than patients undergoing stent grafting for aneurysms or other indications.
Conclusions: Thoracic aortic stent grafting has evolved to be a viable option to complement, augment, or even
replace traditional treatments for aortic disease. These data illustrate the applicability of this evolving technol-
ogy in the establishment of new treatment paradigms for complex aortic pathologies. (J Thorac Cardiovasc Surg
2011;142:587-94)Thoracic endovascular aortic repair (TEVAR) has evolved
during the past 15 years from hand-sewn experimental de-
vices1 to become the predominant technique for repair of
most thoracic aortic pathology. We began the TEVAR pro-
gram at the University of Pennsylvania in 1999, initially
treating patients enrolled in pivotal trials with atheroscle-
rotic aneurysms and occasional uses of stent grafts for other
indications in dire emergencies. After the first TEVARe Departments of Cardiovascular and Vascular Surgery, Hospital of the Uni-
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The Journal of Thoracic and Cadevice approval in March 2005 (Gore TAG thoracic nitinol
endograft; WL Gore & Associates, Inc, Flagstaff, Ariz), we
expanded our indications to include a variety of aortic pa-
thologies, such as type B dissections, transections, hybrid
arch replacement, and hybrid treatment of the proximal de-
scending thoracic aorta in acute type A dissections.2 We
present our experiences with TEVAR over the past decade
with an emphasis on comparing the differential impact of
aortic pathologic diagnosis on early and late outcomes.MATERIALS AND METHODS
Surgical Technique
TEVAR at the Hospital of the University of Pennsylvania is performed
by amultidisciplinary team, including cardiovascular surgery, vascular sur-
gery, cardiovascular anesthesia, neurology, and diagnostic radiology. The
majority of cases were performed in a dedicated hybrid operating room
able to accommodate fixed, high-quality, floor-mounted image intensifier
transesophageal echocardiography equipment, intravascular ultrasound,
neuromonitoring equipment, and a cardiopulmonary bypass pump if neces-
sary, and multiple movable viewing screens that can simultaneouslyrdiovascular Surgery c Volume 142, Number 3 587
Abbreviations and Acronyms
CI ¼ confidence interval
LSCA ¼ left subclavian artery
OR ¼ odds ratio
TEVAR ¼ thoracic endovascular aortic repair
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Ddisplay angiography, hemodynamics, transesophageal echocardiography,
and intravascular ultrasound. Our techniques of TEVAR for atherosclerotic
aneurysms,3 complicated Stanford type B dissections,4 hybrid arch proce-
dures,5 and DeBakey I aortic dissections6 have been published. Briefly, all
non-emergency patients undergo 3-dimensional reconstruction of contrast
computed tomography scans (M2S, Inc, West Lebanon, NH) for preopera-
tive case planning.
A fairly liberal approach to retroperitoneal access is used in cases of
marginal femoral access, which generally occurred in vessels that were
small, heavily circumferentially calcified, or extremely tortuous. Hybrid
arch replacement cases were generally performed through a side-branch
graft of the ascending aorta,5 and TEVAR during open repairs of DeBakey
type I dissections was performed by deploying the stent just beyond the left
subclavian artery (LSCA) origin under direct visualization of the distal
arch.6 TEVAR for complicated Stanford type B dissections was directed
at sealing the primary intimal tear and reexpansion of the true lumen in
the proximal descending thoracic aorta.4 Intravascular ultrasound was
used to verify presence of the wire in the true lumen before advancement
of stiff wires or the device. Ballooning is avoided in dissection cases. In
general, we aim for 10% to 20% oversize at the proximal landing zone,
which ideally is greater than 2 cm in length (particularly along the lesser
curvature), has no thrombus, is not dissected, and has a consistent diameter.
In instances of planned LSCA coverage, prophylactic left common carotid
artery to LSCA bypass is performed perioperatively. Coiling of the LSCA
from the ipsilateral brachial artery is routine in cases of left common ca-
rotid artery-LSCA bypass at the time of stent insertion.Neuroprotective Strategies
Use of somatosensory evoked potential monitoring was not standard-
ized in this population but evolved into a routine with increasing experi-
ence. Preoperative spinal drains were used in all patients who were
considered high risk for spinal ischemia, including those with previous ab-
dominal aortic aneurysm repair, descending thoracic aortic surgery, or
planned complete aortic coverage from left subclavian to celiac axis
(type C coverage). Descending thoracic aortic coverage is classified as
type A, LSCA to midthoracic aorta (T6); type B, midthoracic aorta (T6)
to celiac axis; and type C, left subclavian to celiac axis. The protocol for
management of spinal cord ischemia in the postoperative period included
spinal drainage to cerebrospinal fluid pressure less than 10 cmH2O and ag-
gressive blood pressure augmentation with mean arterial pressures greater
than 90 mm Hg.7Statistical Methods
The University of Pennsylvania TEVAR Registry is a prospectively
maintained perioperative database of thoracic aortic stent-graft procedures.
The details of operative procedures are entered and verified by the attend-
ing surgeon. Outcomes are verified by the attending surgeon, and neuro-
logic outcomes are verified by an attending neurologist with supportive
imaging. Early outcomes were compared using standard univariate statis-
tics, including the Student t test for continuous data and Fisher exact test
for categoric data. Multivariate analyses for predictors of operative mortal-
ity, stroke, and paraplegia were determined using logistic regression. All
variables deemed clinically relevant were maintained in the model, and588 The Journal of Thoracic and Cardiovascular Surgno automated selection procedures were used. Model discrimination was
evaluated with the c-statistic, and model fit was evaluated with the Hosmer
and Lemeshow goodness of fit test. Late survival was analyzed using the
Kaplan–Meier survival technique, and multivariate predictors of late sur-
vival were determined using Cox proportional hazards modeling. Late sur-
vival data were determined using a linkage to the national Social Security
Death Index. The institutional review board at the University of Pennsylva-
nia approved the study and waived the need for patient consent.
RESULTS
Patient Demographics and Operative Characteristics
We performed 502 thoracic aortic stent grafting proce-
dures from April 1999 to April 2009. Pathologic diagnosis
leading to aortic stent grafting included thoracic aneurysms
(64%), complicated acute type B dissections (9.7%),
chronic type B dissections (2.4%), penetrating atheroscle-
rotic ulcers (1.4%), pseudoaneurysms (3.0%), arch hybrids
(5.2%), type A dissections (9.5%), traumatic transections
(3.2%), TEVAR reoperations (4.7%), and other indications
including 2 ascending aortic stents (1.2%).
Patient demographic characteristics are summarized in
Table 1. Patients’ mean age at the time of TEVAR was
70.1  12.4 years, and 51% of patients were aged more
than 70 years. Some 41% of patients were female, and
the majority of patients (87%) were hypertensive.
Stent grafts used included the Gore TAG (WL Gore &
Associates, Inc, Flagstaff, Ariz) (346/502, 69%), Med-
tronic Talent (Medtronic Inc, Minneapolis, Minn) (87,
17%), Medtronic Valiant (Medtronic Inc) (19, 3.4%),
Cook Zenith (Cook Medical, Inc, Bloomington, Ind) (35/
502, 7%), and others (15/502, 3.0%). Access locations in-
cluded right femoral artery (51%), left femoral artery
(17%), right common iliac artery (12%), left common iliac
artery 11%, and others (8%), including abdominal aorta,
ascending aorta (hybrid procedures or type A dissection
stents), and left ventricular apex.8 Aortic coverage included
40% type A (LSCA to T6), 23% type B (midthoracic aorta
to celiac axis), and 37% type C (left subclavian to celiac
axis).
Early Outcomes
Perioperative outcomes are summarized in Table 2. Over-
all 30-day mortality was 10.1%. Significant multivariable
risk factors for 30-day mortality included urgent/emergency
operation (odds ratio [OR], 4.9; confidence interval [CI],
2.2–11.2), type A dissection (OR, 3.4; CI, 1.1–10.9), perio-
perative spinal ischemia (OR, 4.8; CI, 2.1–11.1), type C aor-
tic coverage (OR, 2.1; CI, 1.0–3.4), hybrid arch operation
(OR, 2.7; CI, 1.0–9.0), aortic transection (OR, 10.3; CI,
2.3–25.5), chronic renal failure (OR, 6.2; CI, 2.7–14.9),
and age (by year) (OR, 1.05; CI, 1.0–1.08) (Table 3).
Neurologic complications included permanent complete
or incomplete paraplegia in 17 patients (3.4%), reversible
spinal cord ischemia in 26 patients (5.1%), transient
stroke in 16 patients (3.2%), and permanent stroke in 23ery c September 2011
TABLE 1. Patient demographics
Characteristic No. (%)
Age (mean  SD) 70.1  12.4 y
Age>70 y 297 (51%)
Female sex 208 (41%)
Diabetes 90 (18%)
Hypertension 436 (87%)
COPD 109 (27%)
CRF 50 (10%)
Smoking 267 (53%)
Elective operation 336 (67%)
Urgent operation 60 (12%)
Emergency operation 95 (19%)
Salvage operation 10 (2.0%)
Type of procedure
 Atherosclerotic aneurysm 323 (64%)
 Complicated type B dissection 39 (7.7%)
 Chronic type B dissection 30 (6.0%)
 Hybrid arch 26 (5.2%)
 Transection 16 (3.2%)
 Type A dissectionþstent 40 (8.0%)
 Penetrating ulcer 7 (1.4%)
 Pseudoaneurysm 15 (3.0%)
 Other 6 (1.2%)
Early cohort 251 (50%)
Late cohort 251 (50%)
Aortic coverage:
 Type A coverage 201 (40%)
 Type B coverage 115 (23%)
 Type C coverage 186 (37%)
LSCA bypass 141 (28%)
Redo stent graft 24 (4.7%)
Intraoperative spinal drain 160 (32%)
COPD, Chronic obstructive pulmonary disease; CRF, chronic renal failure; SD, stan-
dard deviation. Type C coverage is coverage of the entire thoracic aorta from the left
subclavian artery orifice to the celiac artery.
TABLE 2. Perioperative outcomes
Characteristic
Stroke/TIA
n (%)
Permanent
paraplegia
n (%)
Early
mortality
n (%)
All patients (n ¼ 502) 39 (7.8%) 17 (3.4%) 50 (10.1%)
Age>70 y (n ¼ 297) 26 (8.8%) 12 (4.0%) 35 (11.8%)
Female sex (n ¼ 208) 70 (9.6%) 6 (2.9%) 25 (12.0%)
Diabetes (n ¼ 90) 7 (7.8%) 4 (4.4%) 10 (11.1%)
Hypertension (n ¼ 436) 38 (8.7%) 15 (3.4%) 43 (9.8%)
COPD (n ¼ 109) 12 (11.0%) 6 (5.5%) 12 (11.0%)
CRF (n ¼ 50) 4 (7.1%) 9 (18.0%) 12 (24%)
Smoking (n ¼ 267) 21 (7.9%) 12 (4.5%) 18 (6.7%)
Elective operation (n ¼ 336) 23 (6.9%) 13 (3.9%) 21 (6.3%)
Urgent operation (n ¼ 60) 8 (12.7%) 1 (1.8%) 4 (6.2%)
Emergency operation (n¼ 95) 9 (9.8%) 2 (2.2%) 19 (19.5%)
Salvage operation (n ¼ 10) 0 (0%) 1 (10%) 6 (60%)
Type of procedure
 Atherosclerotic aneurysm
(n ¼ 323)
21 (6.8%) (3.1%) 31 (9.9%)
 Complicated type B
dissection (n ¼ 39)
2 (5.1%) 2 (5.1%) 3 (7.7%)
 Chronic type B dissection
(n ¼ 30)
2 (6.6%) 1 (3.3%) 2 (6.6%)
 Hybrid arch (n ¼ 26) 2 (7.7%) 3 (11.5%) 4 (15.4%)
 Transection (n ¼ 16) 1 (6.3%) 1 (6.3%) 4 (25%)
 Type A dissectionþstent
(n ¼ 40)
6 (15%) 0 (0%) 6 (15%)
 Penetrating ulcer (n ¼ 7) 1 (14.2%) 0 (0%) 0 (0%)
 Pseudoaneurysm (n¼ 15) 3 (20%) 0 (0%) 0 (0%)
 Other (n ¼ 6) 0 (0%) 0 (0%) 0 (0%)
Early cohort (n ¼ 251) 26 (10.4%) 9 (3.6%) 21 (8.3%)
Late cohort (n ¼ 251) 14 (5.6%) 8 (3.2%) 28 (11.4%)
Aortic coverage
 Type A coverage
(n ¼ 201)
9 (4.1%) 4 (1.9%) 16 (7.8%)
 Type B coverage
(n ¼ 115)
5 (4.6%) 5 (4.6%) 11 (9.2%)
 Type C coverage
(n ¼ 186)
21 (11.4%) 7 (3.5%) 24 (12.8%)
LSCA coverage (n ¼ 141) 11 (7.6%) 4 (3.1%) 13 (9.0%)
No LSCA coverage (n ¼ 361) 36 (10.1%) 14 (4.0%) 35 (9.7%)
Redo stent graft (n ¼ 24) 3 (12.5%) 0 (0%) 1 (4.2%)
Intraoperative spinal drain
(n ¼ 160)
11 (7.0%) 8 (5.0%) 14 (8.8%)
COPD, Chronic obstructive pulmonary disease; CRF, chronic renal failure; TIA, tran-
sient ischemic attack.
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tive permanent and transient stroke included hypertension
(OR, 6.8; CI, 1.0–34), type A dissection (OR, 6.8; CI,
1.9–23), chronic renal failure (OR, 2.5; CI, 1.0–6.7),
known cerebrovascular disease (OR, 4.5; CI, 1.8–11.1),
and increased aortic (type C) coverage (OR, 2.6; CI,
11.2–6.0) (Table 4). Multivariable risk factors for perio-
perative permanent and transient paraplegia included com-
plicated type B dissection (OR, 3.0; CI, 1.1–8.1), hybrid
arch procedures (OR, 3.4; CI, 1.1–10.7), aortic transection
(OR, 2.0; CI, 1.1–17.4), chronic renal failure (OR, 3.7; CI,
1.6–8.9), and smoking (OR, 2.8; CI, 1.2–6.5). Greater
extent of aortic coverage was not associated with risk of
spinal cord ischemia after adjustment for other factors
(Table 5).
At the index procedure, 70 patients (13.9%) had endo-
leaks, of which 35 were proximal and 18 were distal type
I endoleaks, and 6 were type II endoleaks and 11 were
type III interjunctional leaks. Of the 64 type I and III leaks,The Journal of Thoracic and Ca43 (67%) were resolved at the index procedure with addi-
tional ballooning or placement of another stent graft.
To delineate the effect of greater operative experience
with TEVAR on outcomes, we compared the outcomes
of the first 251 patients undergoing TEVAR (early cohort)
with the more recent 251 patients (late cohort). Overall, the
late cohort was older; more likely to undergo emergency
procedures, type A dissections, and transections; and
more likely to have chronic renal failure and to be
smokers. Despite this, as outlined in Figure 1, accessrdiovascular Surgery c Volume 142, Number 3 589
TABLE 3. Multivariate predictors of operative mortality using
logistic regression
Odds Ratio 95% CI P value
Age 1.05 1.01–1.08 .01
Female sex 1.5 0.75–2.8 .26
Diabetes 1.1 0.48–2.5 .82
Hypertension 0.8 0.3–3.7 .64
COPD 1.7 0.78–3.7 .18
CRF 6.2 2.7–14.9 .0001
Smoking 0.79 0.6–01.1 .35
Type of procedure (vs aneurysm)
 Complicated type B
dissection
0.86 0.27–2.7 .8
 Hybrid arch 2.7 1.1–9.0 .03
 Transection 10.3 2.3–25.5 .002
 Type A dissection 3.4 1.1–10.9 .03
Later cohort 1.4 0.7–2.9 .3
Redo stent graft 1.2 0.3–4.8 .7
Type C coverage 2.3 1.0–3.4 .05
Perioperative paralysis/
paraparesis
4.8 2.1–11.1 .004
Urgent/emergency 4.9 2.2–11.2 .001
COPD, Chronic obstructive pulmonary disease; CRF, chronic renal failure. Hosmer-
Lemeshow goodness of fit c2 ¼ 7.7, P ¼ .5, C-statistic ¼ 0.83. Cohort (early vs late)
comparison of first 251 cases with second 251 cases using the earlier cohort as the
reference value. Type C coverage is coverage of the entire thoracic aorta from the
left subclavian artery orifice to the celiac artery.
TABLE 5. Multivariate predictors of perioperative paraplegia
(permanent and transient)
Odds Ratio 95% CI P value
Age 1.01 0.97–1.1 .6
Female sex 1.6 0.8–3.3 .14
Diabetes 0.78 0.3–1.9 .6
Hypertension 0.8 0.2–2.2 .6
COPD 1.4 0.7–3.1 .3
CRF 3.7 1.6–8.9 .002
Smoking 2.8 1.2–6.5 .01
Type of procedure (vs atherosclerotic aneurysm)
1. Complicated type B
dissection
3.0 1.1–8.1 .02
2. Hybrid arch 3.4 1.1–10.7 .03
3. Transection 2.0 1.1–17.4 .04
4. Type A dissection 1.2 0.3–5.2 .7
Later cohort 1.3 0.6–2.7 .4
Urgent/emergency 0.8 0.4–2.0 .7
Type C coverage (vs type A
coverage)
1.1 0.5–2.6 .7
Type B coverage (vs type A
coverage)
1.5 0.6–3.7 .4
COPD, Chronic obstructive pulmonary disease; CRF, chronic renal failure. Hosmer-
Lemeshow goodness of fit c2¼ 4.6, P¼ .08, C-statistic¼ 0.73. Cohort (early vs late)
comparison of first 251 cases with second 251 cases using the earlier cohort as the
reference value. Type C coverage is coverage of the entire thoracic aorta from the
left subclavian artery orifice to the celiac artery.
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stroke were reduced in the late cohort. Mortality and para-
plegia rates were similar in both cohorts despite increasing
complexity.TABLE 4. Multivariate predictors of perioperative stroke (permanent
and transient)
Odds Ratio 95% CI P value
Age (decile) 1.02 0.98–1.06 .2
Female sex 1.4 0.7–3.0 .3
Diabetes 1.1 0.4–2.6 .9
Hypertension 6.8 1.0–34 .05
COPD 1.9 0.8–4.3 .12
CRF 2.5 0.94–6.7 .05
Smoking 0.8 0.4–1.9 .7
Type of procedure (vs aneurysm)
1. Complicated type B
dissection
0.8 0.2–2.7 .7
2. Hybrid arch 1.5 0.3–7.4 .6
3. Transection 4.7 0.5–33 .18
4. Type A dissection 6.8 1.9–23 .002
Later cohort 0.43 0.2–0.95 .04
History of cerebrovascular
disease
4.5 1.8–11.1 .009
Type C coverage 2.6 0.8–4.9 .029
Urgent/emergency 1.7 0.7–4.3 .2
COPD, Chronic obstructive pulmonary disease; CRF, chronic renal failure. Hosmer–
Lemeshow goodness of fit c2 ¼ 7.7, P ¼ .4, C-statistic ¼ 0.77. Cohort (early vs late)
comparison of first 251 cases with second 251 cases using the earlier cohort as the
reference value. Type C coverage is coverage of the entire thoracic aorta from the
left subclavian artery orifice to the celiac artery.
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Overall survival was 51% at 9.8 years. The median
follow-up period was 25.3 months (interquartile range,
9.8–41.7 months), providing 1171 patient-years of follow-
up. As illustrated in Figure 2, patients undergoing TEVAR
for type B dissection were more likely to survive than those
undergoing TEVAR for aneurysms or all other indications.
Risk factors for late mortality determined by Cox propor-
tional hazards modeling included urgent/emergency index
operation (OR, 2.7; CI, 1.8–4.1), hybrid procedures (OR,
2.1; CI, 1.1–4.2), aortic transection (OR, 3.6; CI, 1.1–9.1),
age (years) (OR, 1.05; CI, 1.03–1.07), perioperative paraly-
sis (OR, 1.5; CI, 1.0–2.3), and chronic renal failure (OR,
2.4; CI, 1.4–4.1). Patients undergoing stent grafting for
type B dissection were more likely to survive (OR, 0.6;
CI, 0.3–0.98) than patients undergoing stent grafting for an-
eurysms or other indications. Residual endoleak was not as-
sociated with late mortality (OR, 1.1; CI, 0.5–2.5) (Table 6).DISCUSSION
Traditional open repair of the thoracic aorta is associated
with significant morbidity and mortality. Since the use of
the first homemade thoracic aortic stent graft at Stanford
University in 1992,1 stent-graft technology has evolved
with multiple manufacturers, smaller, more flexible deliv-
ery systems, improved device conformability, less porosity,
and a greater variety of sizing options.9 Evolution of theery c September 2011
FIGURE 1. Perioperative outcomes stratified according to early (first 251 patients) or late (last 251 patients) cohort.
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cular surgeons, cardiovascular anesthesia, diagnostic radi-
ology, and neurologists has enabled application of this
technology to sicker patients while maintaining outcomes.
The current study has demonstrated the outcomes of
‘‘real-world’’ use of TEVAR from the University of Penn-
sylvania TEVAR Registry. Our principle finding in this re-
port is that variability of outcomes for TEVAR is highly
dependent on the initial indication for operation. We found
that operative mortality was higher in patients undergoing
TEVAR for hybrid arch replacement, traumatic transection,
and acute Stanford type A dissection, findings that are not
surprising given the higher acuity and anatomic complexity
in these patients. Hybrid arch replacement and traumaticFIGURE 2. Long-term survival stra
The Journal of Thoracic and Catransection repair were also more likely to be associated
with perioperative paraplegia. In the longer term, patients
with TEVAR for type B dissection complicated by limb
or visceral malperfusion, refractory hypertension or pain,
or rupture or impending rupture had improved survival
compared with patients with aneurysmal or other
indications.
In the literature, results of endovascular treatment of mal-
perfusion with thoracic aortic stent grafts have been highly
favorable compared with open surgery, and endovascular
repair is now the treatment of choice for these extremely
high-risk and complex patients.5,10-12 TEVAR, in
combination with other endovascular interventions, can
successfully seal the entry tear, thrombose the thoracictified by indication for TEVAR.
rdiovascular Surgery c Volume 142, Number 3 591
TABLE 6. Multivariate predictors of long-term survival using Cox
proportional hazards regression
Hazard Ratio 95% CI
Age 1.05 1.03–1.07
Female sex 1.1 0.8–1.6
Diabetes 1.1 0.7–1.7
Hypertension 1.1 0.6–1.9
COPD 1.3 0.88–1.98
CRF 2.4 1.4–4.1
Smoking 0.98 0.7–1.4
Type of procedure (vs aneurysm)
1. Complicated type B
dissection
0.6 0.3–0.98
2. Hybrid arch 2.1 1.1–4.2
3. Transection 3.5 1.3–9.3
4. Type A dissection 1.4 0.6–2.9
Paralysis 1.5 1.0–2.3
Type C coverage 1.0 0.7–1.7
Residual endoleak 1.1 0.5–2.5
Urgent/emergency operation 2.7 1.8–4.1
COPD, Chronic obstructive pulmonary disease; CRF, chronic renal failure. Cohort
(early vs late) comparison of first 251 cases with second 251 cases using the earlier
cohort as the reference value. Type C coverage is coverage of the entire thoracic aorta
from the left subclavian artery orifice to the celiac artery.
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syndromes.10 Longer-term follow-up has shown favorable
remodeling of the aorta in acute type B dissection patients
treated with TEVAR, which has prompted interest in using
TEVAR for treatment of uncomplicated cases to prevent the
5- to 15-mm/year aortic dilatation growth rate observed in
medically treated cases.13 Although we have not used TE-
VAR for asymptomatic acute type B dissections to date,
clinical trials to assess TEVAR for this indication are cur-
rently under way.
Our group, along with others, has also been proactive to
explore the use of TEVAR in emerging indications, includ-
ing hybrid arch repair in very high-risk patients undergoing
open arch repair14,15 and to deploy a stent graft in the
proximal descending thoracic aorta at the time of open
DeBakey type I acute aortic dissection repair.6,16 We do
this to fully reexpand the true lumen/thrombose the false
lumen in the thoracic aorta and exclude the portion of the
aorta that is most likely to dilate in longer-term follow-
up.17 We have shown that this method may limit further
dilatation of the proximal descending thoracic aorta. Our
experience with hybrid arch replacement has been some-
what mixed, with improved results in exceedingly high-
risk elderly patients but little benefit to this approach in
younger patients.14
The significant impact of chronic renal failure on early
and late death, stroke, and paraplegia was striking and has
led to a reevaluation of use of this treatment in this subset
of patients if they are asymptomatic. As discussed by
Svensson and colleagues18 in the 2007 Expert Consensus
Document on the Treatment of Descending Thoracic Aortic592 The Journal of Thoracic and Cardiovascular SurgDisease Using Endovascular Stent-Grafts, use of TEVAR in
patients in whom the anticipated longer-term outcomes are
exceedingly poor may only prevent aneurysm-related death
but not prevent death from other causes. We now tend to
avoid TEVAR in patients who are otherwise higher risk
with concomitant chronic renal failure. The elevated risk
in patients with chronic renal failure is likely a result of ag-
gravation of poor renal function from intravenous contrast
loads, hemodynamic shifts, and the severe microvascular
disease found in these patients. In previous work by our
group, serum creatinine greater than 2.0 was associated
with elevated risks of major adverse events after TEVAR.19
In our analysis, we noted a significant learning curvewith
respect to clinical outcomes. By comparing our first 251 pa-
tients with our last 251 patients, we observed fewer access
complications, strokes, and endoleaks in the latter cohort.
With regard to access complications, after initial experi-
ences with inability to advance the device or arterial trauma
from the device, we adopted a strategy of defaulting to ret-
roperitoneal iliac exposure for access with or without sew-
ing a conduit. In our early experience with TEVAR for
severely atherosclerotic aneurysms, we found a prohibitive
stroke risk in patients with grade IV atheroma in the arch
and no longer offer TEVAR to these patients.7 We also be-
came more aggressive managing endoleaks, particularly
type 1 endoleaks, with placement of additional cuffs or bal-
looning at the index procedure to ensure a good seal.20
CONCLUSIONS
The outcomes of TEVAR are variable and dependent on
the nature of the initial aortic pathology. Our experiences
over the past 10 years have led to systematic improvements
in our outcomes despite offering this therapy to a wider va-
riety of patients with varying operative indications. Stent-
graft design, surgical technique, and perioperative medical
care continue to evolve, but surgeons must maintain a vigi-
lant approach to prospective investigations and long-term
follow-up to ensure optimum patient outcomes with this
technology.
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Dr Craig Miller (Stanford, Calif). For those of you who don’t
know, Nimesh Desai is a Canadian surgeon who went across the
border to Philadelphia for advanced cardiovascular surgical train-
ing. He is going to join the staff at Penn in July. This was a nice
presentation with a lot of information, which has generated in
my mind a lot of questions. I think you are Eastern Canadian,
right? Ontario?
Dr Desai. Yes.
Dr Miller. First, especially with respect to those survival
curves, your numbers are fairly robust out to 3 to 4 years, but I
wish you would have amputated everything beyond that time be-
cause you just don’t have enough patients remaining at risk to sup-
port meaningful inferences. The median follow-up was 25 months,
so this is really a short-term follow-up study, albeit still valuable.
That is a word of caution.The Journal of Thoracic and CaNumber two, it is a heterogeneous substrate that has both
strengths and weaknesses. Most would say that is a weakness,
and you may be comparing apples with prunes with tomatoes.
Conversely, I think there are some strengths to be derived from
this heterogeneous substrate. Number one, the most compelling
good news here is something we hoped for in October 1996
when Michael Dake and I did our first thoracic aortic stent graft
for acute complicated type B dissection (our early experience
was subsequently published in 1999, or 10 years ago): Thoracic
aortic stent grafts are going to save more lives in the very sick pa-
tients with acute complicated type B dissection than they are in any
of the other pathologic subsets. That goes against traditional think-
ing, but I think your data have demonstrated this clearly. Although
none of the clinically available stent grafts in the United States are
approved by the Food and Drug Administration for this indication
(it is all off-label), this application is probably where TEVAR is
going to prove to be the most life-saving. It is also a topic that
has never been tested in a randomized clinical trial. Patients with
acute (<14 days) type B dissection are now being randomized in
Germany and Scandinavia in the ADSORB trial comparing TE-
VAR with best medical therapy, but patients with complicated
acute type B are excluded, so there is more to be learned.
Now, what about the negatives of the heterogeneous substrate?
For example, for your hybrid arch cases, the results aren’t pretty.
On the basis of your analysis, where should you change your prac-
tice and abandon or give up stent grafting? Your results are not
unique because all hybrid thoracoabdominal and hybrid arch TE-
VAR results are poor, and this hybrid approach is rapidly being
abandoned by most authorities. How can we get these patients to
a center that can reproducibly perform a relatively safe and durable
open surgical arch or open thoracoabdominal repair? There are
many hospitals in the United States where the thought of putting
a patient on the pump and cooling them down for profound hypo-
thermic circulatory arrest for total arch or thoracoabdominal aortic
replacement is analogous to being sent to the gas chamber in San
Quentin prison. Of course this is not true in other centers that have
special expertise and are very experienced. The advocates for con-
tinuing hybrid arch procedures just don’t get this point, and in their
hands they can’t do open repairs with reasonably low risk. How do
we get the patients away from centers like that, or will they con-
tinue what you have tried where it doesn’t work very well? Or, al-
ternatively, where should we say that doing nothing is the most
prudent option for these very old and high risk patients? At Stan-
ford we continue to stand by our statement 5 years ago that asymp-
tomatic patients who are judged inoperable for open aortic graft
replacement because of multiple other medical problems should
not be offered TEVAR because treatment will not improve quality
of life and their 5-year life expectancy is dismal secondary to the
other comorbidities.
Dr Desai. I want to thank Dr Miller for his comments. He has
been a thought leader in our field of aortic surgery and cardiac sur-
gery in general for a long time.
With regard to hybrid procedures, as Dr KariyanaMilewski pre-
sented fromour groupat theAmericanAssociation of Thoracic Sur-
gery this year, we don’t see a benefit in doing hybrid procedures for
arch surgery in what I would still call higher risk but younger pa-
tients, those aged less than70years.Our data showed that in patients
aged more than 70 years who are also high risk for other reasons,rdiovascular Surgery c Volume 142, Number 3 593
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thoughwe don’t really knowwhat their long-term survivalwould be
without any procedure at all. This brings up another point, which is
when we compare all of this technology with itself, using different
indications, or other open operations, we have overlooked the big-
gest control group, which is the medically treated group. Our ap-
proach in terms of offering hybrid arch operations today is in the
person who is prohibitively high risk only. It is our experience
that it is not an ideal solution in a younger patient, even though it
may be a ‘‘less invasive’’ or a more convenient operation, particu-
larly for practitioners who are not trained to use circulatory arrest.
Dr Miller. You described 2 other substrates where the results
are not so good, probably because the patients are sicker. That is
one thing that has changed over the last 10 years: You are pushing
the envelope, taking on cases today you wouldn’t have even
dreamed about stent grafting 10 years ago. One of these subsets
is acute traumatic aortic transection. You only had 16 in this series,
and the results were not good in terms of paraplegia, early death,
and late death. I assume they all had TEVAR because you were
forced to do something (eg, rupture or other life-threatening major
complication). If these patients have multiple other injuries and no
life-threatening emergency complication related to the aorta, we
need to remember there remains a role for expectant negative ino-
tropic, controlled hypotension management followed by elective
open surgical graft replacement weeks or even months later.
Have you backed off emergency TEVAR for your acute aortic
tear cases? Believe it or not, not every patient has to be treated
with an emergency stent graft, a practice that unfortunately is be-
coming popular around the world. The long-term durability of TE-
VAR in these patients who generally are very young is dubious at
best. If you don’t have a life-threatening emergency right under
your nose, what about treating them medically, stabilizing them,
get them to where you can do a more definitive and durable
open operation with minimal risk?
Dr Desai. In younger patients, that is our preferred approach, to
stabilize them medically and perform an open operation when it is
appropriate. It is only in the truly emergency salvage case that we
have been performing TEVAR for a transaction.
Dr Miller. Those are wise words, which I hope all the audience
heard.
Next, when you threw a stent graft into the downstream thoracic
aorta like a frozen elephant trunk in the patients with acute type A
dissection, it also did not work out very well. Has your enthusiasm
for this at the time of open ascending and total arch surgical re-
placement waned in view of the high morbidity and mortality? Ob-
servational data exist demonstrating that doing something in the
downstream thoracic aorta, either with a surgical elephant trunk
graft (as Dr Kazui advocated in patients with Marfan syndrome)
or a stent graft, does not decrease the need for late reoperation
nor increase survival. Has your approach changed on the basis of
this analysis?
Dr Desai. I believe it was at the Southern Thoracic Surgical As-
sociation meeting this year that Dr Pochettino from our group pre-
sented our data on the hybrid type A repair, or so-called frozen
elephant-trunk type A repair. Our initial belief is that this proce-
dure has a future, that we have been able to show there is less di-
latation of the proximal descending thoracic aorta. We have also594 The Journal of Thoracic and Cardiovascular Surgshown it does increase the risk of paraplegia, which is not minor,
and I think this is actually an ideal question to be answered with
a randomized clinical trial, more so than almost any other group
of patients who will undergo TEVAR.
DrMiller. That is a good thought. For now, there is a substantial
price the patient must pay to do so, both in terms of early death and
paraplegia, and the rationale for doing so is based on a notion that
is not proven.
What about the paraplegia risk? It really concerned me to hear
you say that extent of descending thoracic aortic coverage (your
term is extent C coverage from the left subclavian artery to the di-
aphragm) has no apparent adverse effects or increases in the risk of
spinal cord injury. When Frank Criado first published his results
showing that the probability of spinal cord injury increases mark-
edly as one covers more descending aorta with TEVAR, most sur-
geons promptly backed off, and I think patients benefited. But are
you now telling me that with cerebrospinal fluid drainage and other
adjuncts there no longer is an additive adverse risk? I am con-
cerned about that, and I would urge all of us to be cautious, pre-
serve whatever intercostal artery blood flow you can, and not get
carried away with TEVAR covering excessive lengths of descend-
ing aorta. Please note that this admonition does not apply to using
noncovered bare metal stents or the petticoat stent on a Cook TX2
dissection TEVAR system, which ‘‘paves’’ the distal true lumen
down below the stent graft that has covered the primary intimal
tear. We at Stanford like that distal adjunctive approach, but we re-
ally have to do everything we can to minimize the likelihood of
spinal cord injury. Do you still think it is safe to cover large lengths
of descending thoracic aorta?
Dr Desai. It has always been our approach to cover as little as
necessary to get a seal, so in a type B dissection case, for instance,
we do not aim to pave the whole aorta. We will try to cover the en-
try tear, reexpand the true lumen at the most proximal area, but not
bring it all theway down to the celiac access except in cases of rup-
ture. With aneurysm cases, again we try to ensure that we are in
good landing zones for seal but not to cover more than that unless
it is necessary. We do not recommend extending coverage because
it is safe.What we are saying is that in our data set with the patients
we operated on we did not see a difference. Now that may be be-
cause we have had a very proactive group of cardiac anesthetists
and neurologists working with us who are involved in taking
care of neurologic changes in the intensive care unit, which may
not be the case in other centers. There is a complex interaction
among patient-related factors, the original aortic pathology, revas-
cularization of the subclavian when covered, and anatomic consid-
erations, such as previous abdominal aortic aneurysm repair, that
affect whether a patient has a postoperative problem with spinal
cord ischemia. There are a lot of issues there, but in our data set
with our approach we did not see a difference.
Dr Miller. How many times did you actively revascularize the
left subclavian artery before, during, or after TEVAR?
Dr Desai. It varies by indication. In our current experience, any
situation where we are going to cover the left subclavian electively
wewill bypass as a routine onanypatient except in true emergencies.
DrMiller. That is good to hear, and we strongly concur. Thanks
for coming out to the 2009 Western Thoracic Surgical Association
meeting in Alberta, Nimesh.ery c September 2011
